Director, Stem Cell Transplantation
Professor of Pediatrics, University of Pennsylvania School of Medicine
- Department: Pediatrics
- Division: Oncology
- Primary Address:
The Children's Hospital of Philadelphia
Oncology Division, BMT Section
Main Bldg., 8th Floor
34th & CIVIC CENTER Blvd.
Philadelphia, PA 19104
- (215) 590-1000
Allogeneic hematopoietic stem cell transplant
- Professor of Pediatrics at the Children's Hospital of Philadelphia (2004 – present)
- Associate Professor of Pediatrics at the Children's Hospital of Philadelphia (1995 – 2004)
- Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia (1991 – 1995)
- Assistant Professor of Pediatrics, University of Pennsylvania School of Medicine (1988 – 1991)
- M.D., University of Cincinnati (1980)
- B.A., Magna cum laude, University of Pennsylvania (1976)
As the director of the Children's Hospital Blood and Marrow Transplant (BMT) Program, I care for patients who will not be cured without a BMT. I also am involved in clinical research to improve outcomes and decrease risks for our transplant patients.
Our bone marrow transplantation program at The Children's Hospital of Philadelphia is one of the largest and oldest pediatric bone marrow transplant programs in the U.S., with more than 1,200 transplants performed. Our program provides the unique combination of comprehensive patient treatment, multidisciplinary teamwork, innovative research and family support. We have 11 beds in HEPA-filtered rooms in a special HEPA-filtered unit which includes a playroom and family lounge. Our physicians, radiation oncologists, nurse practitioners, donor search coordinator, social worker, nutritionists and child life specialists all work together to provide comprehensive care for each patient.
At Children's Hospital, we are expert in everything related to blood and marrow transplants. We have the ability to collect autologous (self) hematopoietic stem cells from very small children for use in high dose chemotherapy protocols. We have expertise in allogeneic transplants, with matched related donors, unrelated donors and cord blood.
We have various clinical studies open. Our research efforts are directed toward providing better outcomes for children who receive bone marrow transplantation. We have developed special protocols to reduce the risks of complications from graft vs. host disease (GVHD) with an unrelated or partially matched related donor, which gives us the ability to use donors other institutions may not be able to use.
Translational research forms an important part of our program. A drug, sirolimus, was found to be effective in killing lymphoid leukemia in the lab of one of our physicians. This drug was added post transplant to patients with leukemia post transplant to improve outcomes. This pilot study was then taken to the Children's Oncology Group, and is now an important randomized protocol which may improve leukemia free survival. We participate with the University of Pennsylvania's Abramson Cancer Center, and studies have been done to show that donor cells activated by a special process and then given to the patient with relapsed leukemia or lymphoma may have a potent anti-cancer effect. These studies are being expanded.
Our program is accredited by the Foundation for Accreditation of Cell Therapy (FACT). All three components -- clinical, cell collection and stem cell laboratory -- are accredited. FACT accreditation is an extremely rigorous process, and there are few pediatric centers that have all three components on site.
- Dinardo L, Brown V, Perez E, Bunin N, Sullivan KE.. A single-center study of hematopoietic stem cell transplantation for primary immune deficiencies (PIDD). Pediatr Transplant. 2011 [Epub ahead of print] Nov.
- Bunin N, Small T, Szabolcs P, Scott Baker K, Pulsipher MA, Torgerson T. NCI, NHLBI/PBMTC Nov 16, 2011. First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation. Persistent Immune Deficiency in Pediatric Transplant Survivors. Biol Blood Marrow Transplant. 2011 Nov:[Epub ahead of print].
- Nemecek ER, Ellis K, He W, Bunin NJ, Bajwa RS, Cheerva A, Cairo MS, Dvorak C, Duval M, Davies S, Eapen M, Gross TG, Hussein AA, Macmillan ML, Mehta PA, Pulsipher MA, Seber A, Woolfrey AE, Frangoul HA, Carpenter PA.. Outcome of Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation for Childhood Acute Lymphoblastic Leukemia in Third Remission. Biol Blood Marrow Transplant. Vol 17(12) . 2011 Dec:1833-1840.
- Baker KS, Bhatia S, Bunin N, Nieder M, Dvorak CC, Sung L, Sanders JE, Kurtzberg J, Pulsipher MA. Late effects after pediatric hematopoietic cell transplantation: State of the science, future directions. Biol Blood Marrow Transplant. Biol Blood Marrow Transplant. Vol 17(10) . 2011 Oct:1424-1427.
- Mostoufi-Moab S, Ginsberg JP, Bunin N, Zemel B, Shults J, Thayu M, Leonard MB.. Body Composition Abnormalities in Long-Term Survivors of Pediatric Hematopoietic Stem Cell TransplantationAug 10, 2011 (PMID: 21839468). J Pediatrics. 2011 Aug.
- Cable C, Finkel RS, Lehky TJ, Biassou NM, Wiggs EA, Bunin N, Pierson TM. Unrelated umbilical cord blood transplant for juvenile metachromatic leukodystrophy: a 5-year follow-up in three affected siblings. Mol Genet Metab. Vol 102(2) . 2011 Feb:207-209.
- Gilman AL, Jacobsen C, Bunin N, Levine J, Goldman F, Bendel A, Joyce M, Anderson P, Rozans M, Wall DA, Macdonald TJ, Simon S, Kadota RP. Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: A pediatric blood and marrow transplant consortium study. Pediatr Blood Cancer. Vol 57(3) . 2011:506-513.
- Bunin N, Guzikowski V, Rand ER, Goldfarb S, Baluarte J, Meyers K, Olthoff KM: Solid organ transplants following hematopoietic stem cell transplant in children. Solid organ transplants following hematopoietic stem cell transplant in children. Pediatr Transplant. Vol 14(8) . 2010 Dec:1030-1035.
- Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Sakamoto KM, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, Starư J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. Vol 42(9) . 2010 Sep:794-800.
- Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F, Buchanan GR, Bunin N, Dickerhoff R, Giller R, Haut PR, Horan J, Hsu LL, Kamani N, Levine JE, Margolis D, Ohene-Frempong K, Patience M, Redding-Lallinger R, Roberts IA, Rogers ZR, Sanders JE, Scott JP, Sullivan KM; Multicenter Study of Bone Marrow Transplantation for Sickle Cell Disease. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. Vol 16(2) . 2010 February:263-272.